Eagle Asset Management Inc. Invests $613,000 in Novartis AG (NVS) Stock
Eagle Asset Management Inc. acquired a new stake in Novartis AG (NYSE:NVS) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 7,103 shares of the company’s stock, valued at approximately $613,000.
Several other hedge funds have also recently added to or reduced their stakes in NVS. Janus Henderson Group PLC increased its position in shares of Novartis by 42,797.5% in the second quarter. Janus Henderson Group PLC now owns 1,914,516 shares of the company’s stock valued at $159,821,000 after acquiring an additional 1,910,053 shares during the period. Parnassus Investments CA increased its position in shares of Novartis by 18.5% during the third quarter. Parnassus Investments CA now owns 9,447,817 shares of the company’s stock valued at $811,095,000 after buying an additional 1,477,168 shares during the period. FMR LLC increased its position in shares of Novartis by 172.1% during the second quarter. FMR LLC now owns 2,294,782 shares of the company’s stock valued at $191,546,000 after buying an additional 1,451,441 shares during the period. Principal Financial Group Inc. purchased a new position in shares of Novartis during the second quarter valued at about $71,606,000. Finally, BlackRock Inc. increased its position in shares of Novartis by 25.3% during the second quarter. BlackRock Inc. now owns 3,549,783 shares of the company’s stock valued at $296,299,000 after buying an additional 717,186 shares during the period. Hedge funds and other institutional investors own 10.87% of the company’s stock.
Several brokerages recently issued reports on NVS. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis in a research report on Tuesday, September 26th. Zacks Investment Research cut shares of Novartis from a “buy” rating to a “hold” rating in a research report on Thursday, September 21st. Leerink Swann boosted their price target on shares of Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. Cowen set a $90.00 price objective on shares of Novartis and gave the stock a “hold” rating in a research note on Wednesday, August 9th. Finally, Bank of America lowered shares of Novartis from a “neutral” rating to an “underperform” rating in a research note on Wednesday. Four analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the company. Novartis presently has an average rating of “Hold” and an average price target of $85.32.
Novartis (NYSE:NVS) last issued its earnings results on Tuesday, October 24th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.25 by $0.04. The firm had revenue of $12.41 billion for the quarter, compared to the consensus estimate of $12.21 billion. Novartis had a net margin of 13.73% and a return on equity of 15.77%. The business’s revenue was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.23 earnings per share. equities research analysts forecast that Novartis AG will post 4.75 earnings per share for the current year.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.